Association of Psychopharmacological Medication Preference with Autistic Traits and Emotion Regulation in ADHD

Name: Association of Psychopharmacological Medication Preference with Autistic Traits and Emotion Regulation in ADHD
SKU: 26639
Price: 30.00 USD
Availability: InStock

$30.00

Want a discount? Become a member by purchasing Psychopharmacology Bulletin Subscription - Individual!

Categories: Psychopharmacology Bulletin, VOL 53 No. 4 Articles 2023 Tags: Anil Altunkaya, atomoxetine, attention-deficit-hyperactivity-disorder, autistic traits, Beyza Ozbaran, Burcu Ozbaran, emotion dysregulation, Halil Ibrahim Colak, Ipek Inal-Kaleli, methylphenidate, Nurhak Dogan, Sezen Kose

Description

Description

Original Research

Association of Psychopharmacological Medication Preference with Autistic Traits and Emotion Regulation in ADHD

By Burcu Ozbaran, Ipek Inal-Kaleli, Nurhak Dogan, Halil Ibrahim Colak, Anil Altunkaya, Beyza Ozbaran, Sezen Kose

Association of Psychopharmacological Medication Preference with Autistic Traits and Emotion Regulation in ADHD

Description

Original Research

Treatment of Children with Attention-Deficit/Hyperactivity Disorder: Results of a Randomized, Multicenter, Double-Blind, Crossover Study of Extended-Release Dexmethylphenidate and D,L-Methylphenidate and Placebo in a Laboratory Classroom Setting

A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended- Release) in Adolescents with ADHD (OPEN ACCESS)

Agomelatine for Depression in Schizophrenia by Jochen Mutschler

Antipsychotics Case Study by Yuan-Hwa Chou

Association of Psychopharmacological Medication Preference with Autistic Traits and Emotion Regulation in ADHD

Description

Original Research

Related products

Treatment of Children with Attention-Deficit/Hyperactivity Disorder: Results of a Randomized, Multicenter, Double-Blind, Crossover Study of Extended-Release Dexmethylphenidate and D,L-Methylphenidate and Placebo in a Laboratory Classroom Setting

A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended- Release) in Adolescents with ADHD (OPEN ACCESS)

Agomelatine for Depression in Schizophrenia by Jochen Mutschler

Antipsychotics Case Study by Yuan-Hwa Chou